This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
RIPK1 / Receptor-interacting serine/threonine-protein kinase 1 · IHC design guide
Design Immunohistochemistry for RIPK1
Plan RIPK1 IHC in paraffin sections using the observed cytoplasmic tissue pattern and high staining in several glandular cell types as reference points (HPA tissue IHC). Catalog antibody A00141 is validated for human IHC, with a reported concentration of 5–10 μg/mL (datasheet).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
RIPK1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining; high in several glandular cell types (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation conditions consistent (standard IHC practice; not target-specific) | |
| Caveat | Low tissue specificity limits negative-tissue controls (HPA tissue IHC) | |
| Regulation | Expression regulation is unreported (UniProt) | |
| Isoform / epitope | 2 isoforms; antibody epitope coverage is unspecified (UniProt; datasheet) |
Section 1
Recommended RIPK1 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with published RIPK1 IHC methods for rat cerebellum, mouse frozen spleen, and temporomandibular joint specimens (PMC13582310; PMC11071064; PMC10902568).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A00141-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-RIPK1, 2.5 μg/mL (datasheet A00141-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | RIPK1-positive staining in glandular cells of appendix (HPA tissue IHC: High). HPA tissue profile: Ubiquitous cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteFor paraffin sections, start with citrate retrieval at pH 6.0, 95–98 °C for 20 min (page antigen retrieval); optimize with tissue controls.
Section 2
What Is the Expected RIPK1 Staining Pattern?
RIPK1 should appear mainly in the cytoplasm, with possible membrane staining (UniProt Q13546; HPA subcellular). Expect staining in glandular cells of the colon and other listed digestive tissues (HPA: High). HPA describes tissue staining as ubiquitous cytoplasmic expression, with Supported reliability and medium consistency with RNA data (HPA tissue IHC). RIPK1 has no transmembrane segment (UniProt Q13546 topology).
| Cytoplasmic stain in colon glands (HPA: High) | Expected RIPK1 pattern (HPA: ubiquitous cytoplasmic expression). |
| Nuclear-only stain (HPA: cytosol and plasma membrane) | Unexpected compartment; assess nonspecific staining (HPA subcellular; general IHC practice). |
| Strong stain only in cortex endothelium (HPA: Low) | Unexpected enrichment; check cross-reactivity and endogenous activity (HPA tissue IHC; general IHC practice). |
| Uniform stain over cells and blank areas (general IHC practice) | Suggests background; review blocking and detection controls (general IHC practice). |
| No stain in colon glands (HPA: High) | Check tissue controls and staining steps before calling RIPK1 absent (HPA tissue IHC; general IHC practice). |
💡Expected RIPK1 appearanceA positive result shows cytoplasmic staining in colon glandular cells (HPA: High); nuclear-only or blank-area staining is suspect (HPA subcellular; general IHC practice).
| Compartment (UniProt Q13546; HPA subcellular) | Expect cytosol; membrane staining is plausible (UniProt Q13546; HPA subcellular). |
| Tissue contrast (HPA tissue IHC) | Colon glands are High; cortex endothelium is Low (HPA tissue IHC). |
| IHC evidence (HPA antibodies) | HPA015257 and CAB010302 are each Supported for IHC (HPA antibodies). |
| IF/ICC localisation? (HPA subcellular) | Cytosol and plasma membrane are approved locations (HPA ICC-IF). |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in colon glands (HPA: High) | Staining workflow may have failed (general IHC practice). | Check positive control, retrieval and detection steps (general IHC practice). |
| Nuclear-only signal (HPA subcellular) | Possible nonspecific staining (general IHC practice). | Compare with controls and expected cytosol location (HPA subcellular; general IHC practice). |
| Strong stain in cortex endothelium (HPA: Low) | Possible cross-reactivity or endogenous activity (general IHC practice). | Check negative and detection controls (general IHC practice). |
| Blank areas stain (general IHC practice) | Possible detection background (general IHC practice). | Inspect reagent-only control and washing (general IHC practice). |
| Diffuse stain obscures cells (general IHC practice) | Possible excess primary or inadequate blocking (general IHC practice). | Optimize primary dilution and blocking with controls (general IHC practice). |
Experiment evidence
IHC & IF images showing RIPK1 staining
A00141-1 · IHCImmunohistochemistry of RIPK1 in mouse kidney tissue with RIPK1 antibody at 2.5 μg/mL.
A00141-1 · IHCImmunohistochemistry of RIPK1 in mouse kidney tissue with RIPK1 antibody at 2.5 μg/ml.
A00141-1 · IFImmunofluorescence of RIPK1 in Mouse Kidney cells with RIPK1 antibody at 20 μg/mL.
M00141-3 · IHCRat kidney was stained with Anti-RIP rabbit antibody
M00141-3 · IHCHuman cervical carcinoma was stained with anti-RIP rabbit antibody
A00141 · IHCImmunohistochemistry of RIP1 in human placenta tissue with RIP1 antibody at 10 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000137275-RIPK1/tissue/cerebral+cortex#imid_3509928
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000137275-RIPK1/tissue/colon#imid_3509870
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000137275-RIPK1/tissue/liver#imid_3509863
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000137275-RIPK1/tissue/kidney#imid_3509872
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB010302; green = RIPK1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB010302; green = RIPK1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for RIPK1 IHC & IF
🧪Start with colon and assess staining in glandular cells (HPA: High in colon glandular cells). HPA detects RIPK1 in all 45 scored tissues, so use no-primary and isotype controls for the negative comparison; any cells without visible signal on the positive slide should show only counterstain or background and should not be treated as a validated negative population (HPA: no negative tissue rows).
Positive control tissue: Appendix (Glandular cells, HPA High)
Negative control tissue: None in HPA: RIPK1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show RIPK1 in A-431, U-251MG, U2OS, KOLF2.1J, with annotated localisation: Plasma membrane (approved), Cytosol (approved) (HPA subcellular).
Technical controls: Run a no-primary, secondary-only control and a control immunoglobulin matched to the primary antibody’s host species and class; for a monoclonal antibody, match its isotype (standard IHC practice). Confirm specificity with RIPK1 knockout material, or immunizing-peptide competition if the peptide is available; in colon, quench endogenous peroxidase and inspect background before interpreting chromogenic staining (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected mouse kidney IHC caption does not state its fixative (selected-SKU caption: A00141-1). Retrieval dependency is unreported, so optimize antigen retrieval for the chosen paraffin IHC assay; the supplied evidence does not establish that frozen sections or IF/ICC are easier (supplied target/application evidence). Colon glandular and mucus-associated background can complicate chromogenic scoring, so compare signal with the control sections (standard IHC practice).
HPA tissue IHC evidence for RIPK1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
| Gallbladder | Glandular cells | High | Protein (IHC) | HPA → |
| Lung | Alveolar cells type I | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: RIPK1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced RIPK1 IHC Tips
Troubleshoot chromogenic RIPK1 staining in paraffin sections, with a separate check for IF multiplexing and localisation.
How should I retrieve RIPK1 when paraffin sections stain weakly?
Start with citrate buffer at pH 6.0 for heat-induced retrieval at 95–98 °C for 20 minutes (page retrieval rule: cytoplasmic / membrane antigen). Allow slides to cool in retrieval buffer, then compare staining with a section processed without retrieval to assess whether heat improves signal (standard IHC practice). Use a known positive tissue region and keep section thickness, antibody concentration, and chromogen development matched across conditions (standard IHC practice). If staining remains weak, test an alternative retrieval buffer as a fallback in a small side-by-side comparison; excessive heat can damage morphology and increase background (standard IHC practice).
Can fixation explain inconsistent RIPK1 staining between tissue blocks?
Target-specific fixation sensitivity for RIPK1 is unknown from the supplied evidence; the mouse kidney image caption reports antibody concentration but does not state its fixative (A00141-1 tissue-IHC caption). Record each block’s fixative and fixation duration before attributing intensity differences to biology (standard IHC practice). Compare sections from similarly handled blocks using the same pH 6.0 citrate retrieval, antibody concentration, and detection time (page retrieval rule; standard IHC practice). If a weak block also shows poor morphology or broad loss of other expected staining, assess tissue processing and reagent performance before changing the RIPK1 scoring threshold (standard IHC practice).
Where should RIPK1 staining appear, and how should membrane staining be judged?
RIPK1 is annotated in the cytoplasm and at the cell membrane, without a transmembrane segment (UniProt Q13546 localisation and topology). HPA reports ubiquitous cytoplasmic tissue staining and approved cytosol and plasma-membrane locations in cell imaging (HPA tissue IHC; HPA subcellular). Score diffuse cytoplasmic staining and any convincing membrane-associated signal separately, using the same compartment definitions across slides (standard IHC scoring practice). Treat isolated nuclear-only staining or pigment-like deposits as suspect until controls support them, and check that any apparent membrane rim follows intact cell boundaries rather than tissue folds or section edges (UniProt Q13546 localisation; standard IHC practice).
Could epitope placement change what my RIPK1 IHC assay detects?
RIPK1 has 2 annotated isoforms, a kinase domain at residues 17–289, and a death domain at 583–669 (UniProt Q13546). The supplied evidence does not identify the catalog antibody’s epitope or establish equal detection of both isoforms (supplied antibody evidence). Request its immunogen or epitope region and compare that region with the isoform sequences before interpreting unequal staining as isoform-specific expression (standard antibody-validation practice). Several RIPK1 phosphorylation sites are annotated, including residues 161 and 166; do not interpret total-antibody staining as kinase activation without a separately validated modification-specific assay (UniProt Q13546 modified residues; standard IHC interpretation).
How can I check RIPK1 localisation in a multiplex IF experiment?
Plan IF as a separate assay and validate its antibody staining and controls independently of this paraffin-section IHC workflow (standard IF practice). Pair RIPK1 with a validated marker for the cell population being assessed; HPA reports high staining in intestinal glandular cells and lung alveolar type I cells (HPA tissue IHC). Choose a fluorophore channel after checking tissue autofluorescence with an unstained control, and acquire each channel separately to assess bleed-through (standard IF practice). RIPK1 has cytosolic and plasma-membrane locations but no transmembrane segment; if the mapped epitope requires intracellular access, compare mild permeabilisation with an unpermeabilised control while checking membrane preservation (HPA subcellular; UniProt Q13546 topology; standard IF practice).
What should I change when RIPK1 chromogenic staining has high background?
Inspect a no-primary control for detection-system staining, and compare it with the RIPK1 slide at the same chromogen development time (standard IHC practice). For a peroxidase-based assay, include an appropriate endogenous-peroxidase block before DAB development; these are general workflow steps, not RIPK1-specific evidence (standard IHC practice). Titrate the primary antibody and detection incubation on adjacent sections while keeping pH 6.0 retrieval constant, so changes can be attributed to staining conditions (page retrieval rule; standard IHC practice). Diffuse colour outside intact cells, staining concentrated at folds, or deposits in damaged regions should prompt inspection of washing, section integrity, and chromogen timing (standard IHC practice).
How should I quantify RIPK1 across paraffin tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the tissue region and eligible cell population before scoring, then keep exposure, counterstain, and DAB development conditions comparable across sections (standard IHC quantification practice). For cell-based scoring, report the percentage of positive cells and an H-score calculated from percentages in intensity categories 0–3 (standard IHC quantification practice). For spatial analysis, report RIPK1-positive cell density per mm² of viable, analyzable tissue, excluding folds and missing tissue (standard IHC quantification practice). Normalize comparisons to the same cell population or viable tissue area, since HPA describes broadly distributed cytoplasmic RIPK1 staining rather than a tissue-restricted pattern (HPA tissue IHC; standard IHC quantification practice).
How do I distinguish genuine RIPK1 signal from staining artefacts?
Look for staining in intact cell cytoplasm, with possible membrane-associated signal; isolated nuclear-only colour does not match the supplied localisation evidence (UniProt Q13546 localisation; HPA subcellular). Compare the observed cell population with expected tissue patterns: HPA reports high staining in colon glandular cells and low staining in liver cholangiocytes, with medium consistency between staining and RNA data (HPA tissue IHC). Check whether signal persists away from section edges, folds, necrotic areas, and damaged tissue, where apparent positivity can reflect processing artefacts (standard IHC practice). A no-primary control helps identify endogenous-enzyme or detection background; RIPK1 presence alone does not establish pathway activation or necroptosis (standard IHC practice; UniProt Q13546 function).
Boster reagents
Best RIPK1 / Receptor-interacting serine/threonine-protein kinase 1 IHC Antibodies
These antibodies have IHC images from human placenta, mouse kidney, rat kidney, and human cervical carcinoma; one also has a mouse kidney IF image (catalog image captions).
Real IHC data
Anti-RIPK1 Antibody
Cat # A00141-1
Real IHC data
Anti-RIP Rabbit Monoclonal Antibody
Cat # M00141-3
Real IHC data
Anti-RIPK1 Antibody
Cat # A00141
A00141 has an IHC-P image from human placenta, while A00141-1 has an IHC-P image from mouse kidney and an IF image from mouse kidney cells (catalog applications; image captions). M00141-3 lists IHC and IF and has IHC images from rat kidney and human cervical carcinoma, although its stated reactivity is Human (catalog applications; image captions; reactivity).
Which to pick: For human paraffin-section IHC, consider A00141, a polyclonal antibody with a human placenta IHC image; its image caption does not report the fixative (catalog dilution text; applications; own IHC caption). For IF/ICC, start with A00141-1 because it lists IF and has a mouse kidney cell IF image (catalog applications; own IF caption). A00141-1 is also the cross-species IHC-P choice because it lists Human, Mouse, and Rat reactivity and shows mouse kidney IHC; its IHC caption does not report the fixative (catalog applications; reactivity; own IHC caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q13546 (RIPK1_HUMAN, Receptor-interacting serine/threonine-protein kinase 1).
- Human Protein Atlas. RIPK1 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. RIPK1 subcellular location (ICC-IF): Localized to the plasma membrane and cytosol..
- Human Protein Atlas. RIPK1 antibody validation summary (2 antibodies).
- Impact of Losartan Nanoparticles on Carbon Tetrachloride-induced Cerebellar Injury in Rats: Association with Alterations in RIPK1/RIPK3/MLKL Necroptosis Markers. Molecular neurobiology 2026 — PMC13582310.
- Radiosynthesis and characterization of a carbon-11 PET tracer for receptor-interacting protein kinase 1. Nuclear medicine and biology 2022 — PMC11071064.
- An immunohistochemical atlas of necroptotic pathway expression. EMBO molecular medicine 2024 — PMC11250867.
- Alleviation of temporomandibular joint osteoarthritis by targeting RIPK1-mediated inflammatory signalling. Journal of cellular and molecular medicine 2024 — PMC10902568.
- PubMed PMID:8612133 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:14574404 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for RIPK1 (Receptor-interacting serine/threonine-protein kinase 1). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A00141-1 at 2.5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Glandular cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A00141-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-RIPK1, 2.5 μg/mL (datasheet A00141-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation conditions consistent (standard IHC practice; not target-specific); Caveat: Low tissue specificity limits negative-tissue controls (HPA tissue IHC); Isoform / epitope: 2 isoforms; antibody epitope coverage is unspecified (UniProt; datasheet); Regulation: Expression regulation is unreported (UniProt). Evidence: UniProt Q13546, HPA tissue IHC · Supported, HPA ICC-IF · plasma membrane and cytosol., Datasheet A00141-1, PMC13582310, PMC11071064. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/RIPK1/immunohistochemistry-ihc-guide.